中国医疗前沿2013,Issue(6) :62-62,63.DOI:10.3969/j.issn.1673-5552.2013.06.0045

恩他卡朋与吡贝地尔援释片治疗帕金森病异动症的疗效对比

欧阳基鹏 何慧君 侯蕴琪
中国医疗前沿2013,Issue(6) :62-62,63.DOI:10.3969/j.issn.1673-5552.2013.06.0045

恩他卡朋与吡贝地尔援释片治疗帕金森病异动症的疗效对比

欧阳基鹏 1何慧君 1侯蕴琪1
扫码查看

作者信息

  • 1. 528300 广东省佛山市顺德区第一人民医院神经内科
  • 折叠

摘要

目的评定恩他卡朋与吡贝地尔援释片治疗帕金森病异动症的疗效。方法将35例患者随机分为治疗组(添加恩他卡朋)18例、对照组(添加吡贝地尔援释片)17例,对照组给予左旋多巴片加吡贝地尔援释片,治疗组给予左旋多巴片加恩卡他朋。治疗12周后观察临床疗效。结果治疗组疗效明显优于对照组,统计学有显著差异。结论恩他卡朋联合左旋多巴治疗帕金森病异动症患者疗效显著,能明显提高患者生活质量。

Abstract

Objective Compare the efficacy of entacapone and piribedil sustained-release tablets in the treatment of dyskinesia in patients with Parkinson's disease. Methods 35 patients were selected, and 18 cases were randomly divided into treatment group(add entacapone), 17 cases into the control group(add piribedil sustained-release tablets). The control group was given levodopa tablets plus piribedil sustained-release tablets; the treatment group received levodopa tablets and entacapone. Clinical efficacy was observed in the two groups after 12 weeks of treatment. Result The treatment group was significantly better than the control group, a statistically significant difference. Conclusion Entacapone combined with levodopa in the treatment of dyskinesia in patients with Parkinson's disease is more effective than the control group, can significantly improve the quality of life of patients with Parkinson's disease.

关键词

帕金森病/恩他卡朋/左旋多巴/异动症

Key words

Parkinson's disease/Entacapone/Levodopa/Dyskinesia

引用本文复制引用

出版年

2013
中国医疗前沿
中国医院协会

中国医疗前沿

影响因子:0.186
ISSN:1673-5552
被引量8
参考文献量2
段落导航相关论文